Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00653523
Recruitment Status : Completed
First Posted : April 7, 2008
Results First Posted : June 30, 2010
Last Update Posted : May 10, 2017
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and simvastatin in patients with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

Condition or disease Intervention/treatment Phase
Hypercholesterolemia Drug: Ezetimibe Drug: Simvastatin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 151 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Long-term Study of Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors
Actual Study Start Date : December 1, 2007
Actual Primary Completion Date : June 1, 2009
Actual Study Completion Date : June 1, 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Ezetimibe + Simvastatin
Ezetimibe 10 mg + Simvastatin 20 mg
Drug: Ezetimibe
Ezetimibe 10 mg once daily
Other Name: SCH 58235

Drug: Simvastatin
Simvastatin 20 mg daily




Primary Outcome Measures :
  1. Number of Participants With Adverse Events and Adverse Reactions [ Time Frame: Throughout 1 year of study ]

    An adverse event is any unfavorable medical event occurring in a subject to whom an investigational product is administered, and a causal relationship between the administered investigational product and an adverse event is not always clarified.

    That is, an adverse event is any unfavorable or unintended sign (including an abnormal change in laboratory test values), symptom, or disease, and a causal relationship to the relevant investigational product is not considered.

    Any adverse event that was treatment-related was considered an adverse reaction.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with hypercholesterolemia who satisfy the following criteria:

    • Patients who have used any of the following HMG-CoA reductase inhibitors (hereinafter referred to as "statins") for 4 weeks or longer before the start of the observation period and whose LDL-cholesterol level during the treatment had not reached lipid management target indicated below
    • Age: 20 years of age or older (at the time of obtaining informed consent)
    • Sex: both males and females
    • Inpatient/outpatient: Out-patients

Exclusion Criteria:

  • Patients for whom any of the following is applicable:

    • Patients whose fasted triglyceride level measured at the start of the observation period or the treatment period exceeds 500 mg/dL
    • Patients with homozygous familial hypercholesterolemia
    • Patients with creatine phosphokinase (CPK) > 2x upper limit of normal (ULN) measured at the start of the observation period or the treatment period.
    • Patients with serious hepatic disorder, or patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2x ULN measured at the start of the observation period or the treatment period.
    • Patients with a history of hypersensitivity to any ingredient of ezetimibe tablets or simvastatin tablets
    • Pregnant, nursing women, women who may be pregnant, or patients wishing to be pregnant during the study.
    • Patients who have discontinued use of serum lipid lowering agents for less than 4 weeks at the start of the treatment period (8 weeks in the case of probucol). (However, if the patient had taken a serum lipid lowering agent before the test conducted at the start of the observation period, a period of discontinuation of 27 days, or 55 days in the case of probucol, is allowed.)
    • Patients who are using cyclosporine from after the start of the observation period
    • Patients who are using any of the following drug from after the start of the observation period: itraconazole, miconazole, atazanavir, saquinavir mesilate
    • Patients with a history of ezetimibe use
    • Patients with hyperlipidemia associated with the following diseases:

      • Hypothyroidism
      • Obstructive gall bladder or biliary disease
      • Chronic renal failure
      • Pancreatitis
    • Patients with hyperlipidemia associated with concomitant use of drugs having adverse effect on serum lipids, etc
    • Patients who have received an investigational drug within 4 weeks of the start of the observation period
    • Other patients deemed not appropriate for study entry by the investigator
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00653523    
Other Study ID Numbers: P05457
First Posted: April 7, 2008    Key Record Dates
Results First Posted: June 30, 2010
Last Update Posted: May 10, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Simvastatin
Ezetimibe
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors